Cover Image
市場調查報告書

全球核醫學市場:成長,趨勢,預測

Global Nuclear Medicine Market - Segmented by Diagnostics, Therapeutics, Application and Geography - Growth, Trends and Forecasts (2018 - 2023)

出版商 Mordor Intelligence LLP 商品編碼 319327
出版日期 內容資訊 英文 114 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球核醫學市場:成長,趨勢,預測 Global Nuclear Medicine Market - Segmented by Diagnostics, Therapeutics, Application and Geography - Growth, Trends and Forecasts (2018 - 2023)
出版日期: 2018年02月08日 內容資訊: 英文 114 Pages
簡介

核醫學市場預測到2015年將達到16億9,000萬美元。癌症和心臟病的發病率上升,對放射性醫藥品的意識提升,放射性醫藥品的取得成為帶動市場的主要因素。再加上SPECT和PET的認識度提升也加速了市場的成長。

本報告提供全球核醫學市場相關調查,提供您市場概要和規模,促進成長要素,阻礙要素,以及各診斷,治療,用途,地區趨勢,並彙整主要的參與企業競爭環境與簡介等資料。

第1章 簡介

第2章 摘要整理

第3章 市場概要

  • 放射性醫藥品定義
  • 市場規模
  • 市場佔有率
  • 市場趨勢
  • 推動市場的要素
    • 癌症和心臟病的發病率上升
    • 放射性醫藥品的SPECT和PET分析使用擴大
    • 放射性醫藥品的認知度提高
    • 大眾的意識
    • 放射性醫藥品的取得
  • 阻礙市場的要素
    • 放射性醫藥品的半衰期短
    • 高額的資本投資
    • 法律規章指南
    • 給付問題
  • 機會
    • 開發平台的潛在放射性元素
    • 神經學應用的擴大
    • 迴旋加速器生產
  • 威脅
    • 核子反應爐的封閉

第4章 診斷別市場區隔

  • 診斷市場
  • SPECT放射性元素
  • PET放射性元素
  • 氟18

第5章 各個治療市場區隔

  • β輻射體
  • α發射體
  • 近距離放射治療

第6章 各用途市場區隔

  • SPECT
  • PET
  • 治療的應用

第7章 各地區市場區隔

  • 簡介
  • 診斷市場
  • 北美
  • 亞太地區

第8章 競爭環境

  • 收購·合併
  • 新產品上市
  • 協定與聯合
  • 擴大

第9章 市場上龍頭企業

  • Covidien
  • IBA Group
  • Lantheus Medical Imaging
  • Triad Isotopes
  • Siemens Healthcare (PETNET Solutions)
  • NTP Radioisotopes

第10章 企業簡介

  • Bracco Imaging S.P.A.
  • Cambridge Isotope Laboratories, Inc.
  • Cardinal Health, Inc.
  • Covidien, Plc
  • Eczacibasi-Monrol
  • Fujifilm Holdings Corporation
  • Ge Healthcare
  • Iba Group
  • Isotec, Inc. (Sigma-Aldrich)
  • Lantheus Medical Imaging, Inc.
  • Nordion, Inc.
  • Ntp Radioisotopes (PTY), Ltd.
  • Petnet Solutions, Inc.
  • 太陽日酸株式會社
  • Urenco Limited
  • Rotem Industries, Ltd., Inc.
  • 相關機關

第11章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 5562

Description

Nuclear medicine falls under the field of molecular imaging, which involves the usage of very small amount of radioactive material (radiopharmaceuticals) to diagnose and treat disease. In nuclear medicine imaging, the radioisotopes are detected by the special type of cameras attached to the computer, which, in turn, provide very precise pictures of the area of the body examined. The global nuclear medicine market is expected to register a CAGR of 12% during the forecast period, 2018 to 2023.

Increasing Incidence of Cancer and Cardiac Ailments

Increasing incidence of cancer and cardiac ailments are the major drivers for the market. Nuclear medicine shows a huge potential in treating cardiac and cancer diseases. According to a survey by National Cancer Institute, the number of new cases of cancer sites was 460 per 100,000 men and woman per year, while the number of deaths was 176 per 100,000 men and women per year. Cardiology applications will continue to demonstrate strong growth in the market.

Other factors, such as increasing SPECT and PET applications and growing public awareness for healthcare are going to drive the market in the future.

Strict Regulatory guidelines

Regulatory requirements pose another hurdle to translational research and clinical investigations. In the United States, all pharmacologic agents, including diagnostic radiopharmaceuticals and radio therapeutics, undergo regulatory oversight by FDA. Radiopharmaceuticals face additional scrutiny and undergo unique regulatory and approval pathways. Sometimes, extensive toxicology testing poses considerable financial burdens for the investigators.

Additionally, reimbursement hurdles for the manufacturer and high capital investment are also restraining the market growth.

North America to Dominate the Market

The nuclear medicine market is segmented by diagnostics, therapeutics, application, and by geography. By geography, it is segmented into North America, Europe, Asia-Pacific, the Middle East & Africa, and South America.

North America is the dominant market for diagnostic radioisotopes. Within North America, the United States is the largest consumer market for radioisotopes, and Canada is the largest producer of Tc-99m.

Key Developments in the Market

April, 2017: IBA Molecular and Mallinckrodt Nuclear Medicine LLC united to create Curium - a world-class provider in nuclear imaging.

October, 2017: Switzerland's Novartis agreed to pay USD 3.9 billion to take over French nuclear medicines business of Advanced Accelerator Applications, aimed to strengthen its cancer treatment activities.

Major Players: CURIUM, LANTHEUS MEDICAL IMGAGING, TRIAD ISOTOPES, SIEMENS HEALTHINEER, BRACCO, CAMBRIDGE ISOTOPE LABORATORIES INC., CARDINAL HEALTH INC., GE HEALTHCARE, NORDION INC., FUJIFILM HOLDINGS CORPORATION, ECZACIBASI-MONROL amongst others.

Reasons to Purchase this Report

Market analysis for the global nuclear medicine market, with region-specific assessments and competition analysis on a global and regional scale.

Analyzing various perspectives of the industry with the help of Porter's five forces analysis

The treatment type that is expected to dominate the market

Regions that are expected to witness fastest growth during the forecast period

Identify the latest developments, market shares and strategies employed by the major market players.

3 months analyst support, along with the Market Estimate sheet in excel.

Customization of the report

This report can be customized to meet your requirements. Please connect with our analyst, who will ensure you get a report that suits your needs.

Table of Contents

1. Introduction

  • 1.1 Market Definition

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview

  • 5.1 Current Market Scenario
  • 5.2 Market Overview
  • 5.3 Porter's Five Force Analysis
    • 5.3.1 Bargaining Power of Suppliers
    • 5.3.2 Bargaining Power of Buyers
    • 5.3.3 Degree of Competition
    • 5.3.4 Threat of Substitution
    • 5.3.5 Threat of New Entrants

6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

  • 6.1 Market Drivers
    • 6.1.1 Increasing Incidents of Cancer and Cardiac Ailments
    • 6.1.2 Increasing SPECT and Pet Applications
    • 6.1.3 Growing Public Awareness for Healthcare
  • 6.2 Market Restraints
    • 6.2.1 Short Half Life of Radiopharmaceuticals
    • 6.2.2 High Capital Investment
    • 6.2.3 Strict Regulatory Guidelines
  • 6.3 Opportunities
    • 6.3.1 Increasing Imaging Technologies
    • 6.3.2 Potential Radioisotopes in Pipeline
    • 6.3.3 Increasing Neurological Applications
    • 6.3.4 Cyclotron Based Production
  • 6.4 Challenges
    • 6.4.1 Shutdown of Nuclear Reactors

7. Market Segmentation

  • 7.1 By Diagnostics
    • 7.1.1 SPECT Market
    • 7.1.2 PET
  • 7.2 By Therapeutics
    • 7.2.1 Alpha Emitters
    • 7.2.2 Beta Emitters
    • 7.2.3 Brachytherapy
  • 7.3 By Application
    • 7.3.1 Diagnostics
    • 7.3.2 Therapeutics
  • 7.4 By Geography
    • 7.4.1 North America
      • 7.4.1.1 US
      • 7.4.1.2 Canada
      • 7.4.1.3 Mexico
    • 7.4.2 Europe
      • 7.4.2.1 Germany
      • 7.4.2.2 UK
      • 7.4.2.3 France
      • 7.4.2.4 Italy
      • 7.4.2.5 Spain
      • 7.4.2.6 Rest of Europe (RoE)
    • 7.4.3 Asia Pacific
      • 7.4.3.1 Japan
      • 7.4.3.2 China
      • 7.4.3.3 India
      • 7.4.3.4 South Korea
      • 7.4.3.5 Australia
      • 7.4.3.6 Rest of Asia Pacific
    • 7.4.4 The Middle East & Africa
      • 7.4.4.1 GCC Countries
      • 7.4.4.2 South Africa
      • 7.4.4.3 Rest of Middle East & Africa
    • 7.4.5 South America
      • 7.4.5.1 Brazil
      • 7.4.5.2 Argentina
      • 7.4.5.3 Rest of South America

8. Competitive Landscape

  • 8.1 Mergers & Acquisitions
  • 8.2 Agreements, Collaborations & Partnerships
  • 8.3 New Product Launches

9. Key Players

  • 9.1 Curium
  • 9.2 Lantheus Medical Imaging
  • 9.3 Triad Isotopes
  • 9.4 Siemens Healthineers
  • 9.5 Bracco
  • 9.6 Cambridge Isotope Laboratories Inc.
  • 9.7 Cardinal Health Inc.
  • 9.8 GE Healthcare
  • 9.9 Nordion, Inc.
  • 9.10 Fujifilm Holdings Corporation
  • 9.11 Eczacibasi-Monrol

10. Future of the Market

Back to Top